Related Experiment Video

Updated: Nov 9, 2025

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.1K

Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis

Duo Xu1,2, Shun-Qing Liang1,2, Zhang Yang1,2

  • 1Division of General Thoracic Surgery, Inselspital, Bern University Hospital, Bern, Switzerland.

Cell Death & Disease
|April 16, 2021
PubMed

Insights

Malignant pleural mesothelioma (MPM) cells rely on BCL-XL for survival. Targeting BCL-XL with BH3 mimetics and blocking autophagy offers a promising new therapeutic strategy for this deadly cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Cancer cells evade programmed cell death, a key mechanism in tumorigenesis.
  • Malignant pleural mesothelioma (MPM) is a lethal thoracic malignancy with limited treatment options.
  • Understanding anti-apoptotic mechanisms is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To investigate the anti-apoptotic mechanisms in MPM.
  • To explore the therapeutic potential of BCL-2 homology domain-3 (BH3) mimetics in MPM.
  • To identify novel therapeutic strategies for MPM.

Main Methods:

  • Integrated analysis of functional genomic data of MPM cells.
  • Quantitative proteomics of patient tumors.
  • In vitro and in vivo studies using A-1155463 (a BCL-XL-selective BH3 mimetic) and hydroxychloroquine (HCQ).

Main Results:

  • BCL-XL was identified as an overexpressed anti-apoptotic driver and oncogenic dependency in MPM.
  • MPM cells with inactivated NF2/LATS1/2 signaling showed increased sensitivity to BCL-XL inhibition.
  • BCL-XL inhibition induced protective autophagy, and combined inhibition with HCQ synergistically enhanced anti-MPM effects.

Conclusions:

  • BCL-XL is a critical survival factor in MPM, driving resistance to apoptosis.
  • A combination therapy targeting BCL-XL and autophagy presents a novel and effective strategy against MPM.
  • This study elucidates resistance mechanisms and suggests a new therapeutic approach for this aggressive cancer.

More Related Videos

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.4K
Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells11:11

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells

Published on: April 25, 2018

8.4K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.3K
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
3.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Phagocytosis of Apoptotic Cells01:17

Phagocytosis of Apoptotic Cells

Cells undergoing apoptosis form apoptotic bodies that must be removed immediately to prevent inflammation, autoimmune diseases, and necrosis. Phagocytosis is carried out by professional phagocytes such as macrophages or  immature dendritic cells. Non-professional phagocytes such as  epithelial cells and fibroblasts also take part in this process; however, they are not as effective as professional phagocytes. 
Normal cells contain receptors that prevent them from being recognized...
4.2K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
7.0K